Investigational Drug Information for Apaziquone
What is the drug development status for Apaziquone?
Apaziquone is an investigational drug.
There have been 9 clinical trials for Apaziquone.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2007.
The most common disease conditions in clinical trials are Urinary Bladder Neoplasms and [disabled in preview]. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Handok Inc., and Handok Pharmaceuticals Co., Ltd.
Summary for Apaziquone
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,478 |
| WIPO Patent Applications | 443 |
| Japanese Patent Applications | 40 |
| Clinical Trial Progress | Phase 3 (2007-04-01) |
| Vendors | 26 |
Recent Clinical Trials for Apaziquone
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) | Spectrum Pharmaceuticals, Inc | Phase 3 |
| A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | Allergan | Phase 3 |
Clinical Trial Summary for Apaziquone
Top disease conditions for Apaziquone
Top clinical trial sponsors for Apaziquone
US Patents for Apaziquone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Apaziquone Development Update and Market Projection
Apaziquone, also known as EO9, is an investigational intravesical drug candidate for non-muscle-invasive bladder cancer. Its late-stage development failed after two Phase 3 trials did not meet their primary efficacy endpoints. No FDA-approved apaziquone product is marketed, no Orange Book listing exists, and no active commercial launch timeline has been established. The candidate’s current market value is therefore highly dependent on whether a sponsor can justify a new clinical strategy and overcome the failed Phase 3 record.
What is the current development status of apaziquone?
Apaziquone is not an approved drug and is not commercially available in the United States or major regulated markets.
The candidate was developed as a single immediate postoperative intravesical instillation after transurethral resection of bladder tumor, or TURBT. The target population was patients with non-muscle-invasive bladder cancer, particularly those at risk of tumor recurrence.
| Item | Apaziquone status |
|---|---|
| Active ingredient | Apaziquone, EO9 |
| Drug class | Bioreductive alkylating agent; indolequinone derivative |
| Route | Intravesical |
| Primary indication studied | Non-muscle-invasive bladder cancer |
| Development stage reached | Phase 3 |
| FDA approval | None |
| Commercial product | None |
| Orange Book listing | None |
| U.S. regulatory exclusivity | None |
| Biosimilar pathway | Not applicable |
| Current market sales | None from an approved product |
Apaziquone requires enzymatic reduction inside cells to generate reactive intermediates capable of damaging DNA. The rationale was that tumor cells with higher reductase activity could be selectively affected after local bladder administration. The clinical program tested a single postoperative dose intended to reduce recurrence after tumor resection.
Why did apaziquone development fail?
Apaziquone’s Phase 3 program did not demonstrate a statistically significant reduction in bladder-cancer recurrence across the principal trial populations.
The program included two large randomized studies commonly identified as SET and SET2. Both evaluated immediate postoperative intravesical apaziquone against placebo after TURBT. The trials were designed to establish recurrence reduction in patients with non-muscle-invasive bladder cancer.
The principal development problem was efficacy consistency. Earlier clinical work suggested a potential reduction in recurrence, but the confirmatory studies did not reproduce the required benefit at the prespecified level. The failure affected the core clinical claim rather than a secondary safety or manufacturing issue.
What were the key apaziquone Phase 3 trials?
| Trial | Clinical setting | Intervention | Outcome |
|---|---|---|---|
| SET | Immediate postoperative treatment after TURBT | Intravesical apaziquone versus placebo | Primary efficacy objective not met |
| SET2 | Immediate postoperative treatment after TURBT | Intravesical apaziquone versus placebo | Primary efficacy objective not met |
| Earlier Phase 2 studies | Non-muscle-invasive bladder cancer | Intravesical apaziquone | Signals of recurrence reduction, but not confirmed in Phase 3 |
The development record illustrates the commercial risk of a single-dose bladder-cancer product whose value depends on a modest recurrence reduction. A product used once after surgery has limited opportunities to compensate for weak efficacy through dosing flexibility, chronic treatment revenue, or additional disease segments.
What is the FDA regulatory status of apaziquone?
Apaziquone has no FDA approval and no publicly established current FDA review pathway.
The Phase 3 failure prevented the candidate from obtaining a commercial indication for non-muscle-invasive bladder cancer. A new sponsor would likely need to generate additional clinical evidence rather than rely on the previous confirmatory data.
FDA regulatory status:
- No approved New Drug Application.
- No approved label.
- No FDA-recognized commercial indication.
- No postmarketing commitments.
- No approved dosage form.
- No current FDA exclusivity period.
- No established generic approval pathway.
The candidate’s prior clinical history could support regulatory discussions, but a new development program would need to address the reasons the earlier trials failed. Potential issues include patient selection, recurrence-risk heterogeneity, timing of postoperative administration, tumor biology, and the magnitude of benefit achievable with a single instillation.
What patents protect apaziquone?
Publicly available commercial information does not establish an active, enforceable U.S. patent estate that would currently support market exclusivity for apaziquone.
Patent protection for a product at this stage would normally involve several categories:
- Composition-of-matter patents covering apaziquone or related quinone compounds.
- Pharmaceutical-composition patents covering the intravesical formulation.
- Method-of-use patents covering recurrence reduction after TURBT.
- Manufacturing patents covering synthesis, purification, or storage.
- Dosing patents covering the timing and concentration of postoperative administration.
The most commercially important protection would have been composition-of-matter coverage. Such patents generally expire earlier than later-filed formulation or method-of-use patents. Because apaziquone was discovered and developed decades ago, any original compound patent is likely expired or close to expiration, subject to the specific patent family, terminal disclaimers, patent-term adjustments, and jurisdiction.
No Orange Book-listed patent protects apaziquone because there is no approved reference product. That means there is no current U.S. Paragraph IV framework tied to an apaziquone product.
Are there formulation patents for apaziquone?
Intravesical formulation protection could cover concentration, solvent system, stability, reconstitution, packaging, or administration timing. Such patents would have limited commercial value without an approved product and validated clinical efficacy.
A formulation patent could still matter if a new sponsor restarts development. Its value would depend on:
- Whether the claims remain unexpired.
- Whether the formulation is necessary for clinical performance.
- Whether a competing sponsor can use a different vehicle.
- Whether the patent claims survive validity and infringement challenges.
- Whether the formulation improves exposure or tolerability over earlier products.
Are there method-of-use patents for apaziquone?
Method-of-use patents could cover treatment of selected non-muscle-invasive bladder-cancer populations, including patients receiving a single postoperative instillation after TURBT. Their practical value is constrained by the negative Phase 3 record and by the ability of competitors to design around patient-selection or dosing claims.
If a new clinical program identifies a biomarker-defined responder population, a later-filed method-of-use patent could become more valuable than the original broad recurrence-prevention claims. That strategy would require clinical evidence linking the biomarker to apaziquone response.
When does apaziquone lose exclusivity?
Apaziquone has no current regulatory exclusivity date because it has never been approved.
The relevant commercial conclusion is different from a conventional patent-expiry analysis:
| Exclusivity category | Current status |
|---|---|
| FDA new chemical entity exclusivity | None |
| Orphan-drug exclusivity | None publicly established |
| Pediatric exclusivity | None |
| Reference-product exclusivity | None |
| Orange Book patent term | None |
| Biosimilar exclusivity | Not applicable |
| Generic launch date | None established |
Any remaining patent rights must be assessed patent family by patent family. A generic manufacturer cannot file an ANDA against an unapproved drug, so the immediate issue is not generic entry. The immediate issue is whether a sponsor can create a registrable, clinically differentiated product before competitors can enter the same field.
Which companies developed or controlled apaziquone?
Apaziquone was associated with Spectrum Pharmaceuticals during its late-stage development. Spectrum was later acquired by Assertio Holdings in 2018. The development history also involved earlier rights holders and collaborators associated with the EO9 program.
The commercial chain has changed over time, which complicates current asset ownership. Public company disclosures from the development period are more reliable for historical control than for present-day licensing status. No active commercial partnership or current launch agreement has been broadly established in public FDA or market sources.
What licensing deals affected apaziquone?
Spectrum obtained rights to develop and commercialize apaziquone in major markets during the earlier development period. The asset was subsequently affected by Spectrum’s corporate transaction history and the discontinuation of the clinical program.
No current licensing transaction has established a commercial relaunch. A new deal would likely be structured as an asset acquisition, regional license, or option agreement contingent on:
- Confirmation of patent ownership.
- Access to clinical data and biological samples.
- A regulatory meeting with FDA or another health authority.
- A redesigned Phase 2 or Phase 3 plan.
- Manufacturing and formulation transfer.
- A defined biomarker or high-risk patient population.
What patent litigation affects apaziquone?
No major active U.S. patent litigation involving an approved apaziquone product is publicly established.
The absence of litigation reflects the absence of a marketed reference product and the failure of the clinical program. Patent disputes could arise if development restarts, particularly around:
- Ownership of legacy compound patents.
- License scope and territorial rights.
- Manufacturing processes.
- Formulation claims.
- New biomarker-defined uses.
- Clinical-trial supply and confidential know-how.
There is no current Paragraph IV litigation timetable because no apaziquone NDA is listed in the Orange Book.
How strong is the apaziquone patent estate?
The patent estate is commercially weak in its current form.
Patent strength is limited by four factors:
- The compound has been in development for many years, reducing the likely remaining term of original composition claims.
- No approved product supports regulatory exclusivity.
- The Phase 3 efficacy failure reduces the value of broad method-of-use claims.
- A competitor could potentially pursue other intravesical agents or alternative delivery schedules.
The estate could become more valuable if a new sponsor develops a proprietary formulation or identifies a biologically defined responder group. That value would be prospective rather than established.
How does apaziquone compare with competing bladder-cancer drugs?
Apaziquone entered a market dominated by established intravesical therapies and newer bladder-directed agents.
| Product or class | Status | Key competitive position |
|---|---|---|
| Bacillus Calmette-Guérin, or BCG | Approved and widely used | Established immunotherapy for high-risk non-muscle-invasive disease |
| Intravesical mitomycin | Approved and used after TURBT | Established chemotherapy option |
| Gemcitabine | Used intravesically; regulatory status varies by indication and market | Low-cost postoperative chemotherapy option |
| Gemcitabine plus docetaxel | Widely used off-label in clinical practice | Increasing adoption in selected settings |
| Nadofaragene firadenovec | FDA approved for certain BCG-unresponsive disease | Gene-therapy option with differentiated mechanism |
| Nogapendekin alfa inbakicept-pmln | FDA approved with BCG for certain BCG-unresponsive disease | Immune-based combination product |
| Apaziquone | Not approved | No current commercial position |
Apaziquone’s proposed advantages were local delivery, single-dose administration, and a mechanism distinct from conventional cytotoxic chemotherapy. Its disadvantages were the failure to show confirmatory efficacy and the availability of established low-cost alternatives.
What generic entry risks exist for apaziquone?
There is no immediate generic-entry risk because no apaziquone reference product is approved.
If the drug were successfully relaunched, generic risk would depend on the structure of the approval:
- A conventional NDA could face an ANDA pathway after applicable exclusivity expires.
- A narrow method-of-use label could limit, but not eliminate, label-based generic competition.
- A proprietary formulation could create formulation-patent litigation.
- A biomarker-defined indication could support later method-of-use patents.
- Compounded or off-label intravesical alternatives could pressure pricing even before formal generic entry.
The most significant competitive threat would likely come from existing intravesical drugs rather than a future apaziquone generic.
What is the market projection for apaziquone?
The base-case market projection is zero near-term revenue because apaziquone has no approval, no active launch program, and no confirmed sponsor pursuing registration.
A relaunch scenario is possible but would require a new clinical program and a differentiated commercial thesis. The addressable market is the non-muscle-invasive bladder-cancer treatment segment, not the entire bladder-cancer market. Commercial value would depend on recurrence reduction, adoption after TURBT, reimbursement, and competition from BCG, mitomycin, gemcitabine, and newer agents.
| Scenario | Probability profile | Commercial outlook |
|---|---|---|
| Base case: no restart | Highest based on public development history | No product revenue |
| Asset relaunch with new Phase 2 program | Low | Development-stage value only |
| Positive biomarker-selected Phase 2 and Phase 3 program | Very low | Potential specialty bladder-cancer product |
| Broad relaunch using prior Phase 3 data without major redesign | Low feasibility | Weak regulatory and commercial case |
A meaningful revenue forecast cannot be supported by current public evidence. Any model assigning peak sales to apaziquone would be speculative because the candidate lacks a validated efficacy population, approval pathway, active sponsor, and launch date.
What manufacturing and intellectual-property barriers remain?
Apaziquone’s manufacturing barriers appear manageable relative to biologic products because it is a small molecule. The principal risks are product quality, formulation stability, sterile manufacturing, and reproducible intravesical delivery.
A relaunch would require:
- Current good manufacturing practice production.
- Validated synthesis and impurity controls.
- Sterile product manufacturing or a validated reconstitution process.
- Stability data supporting hospital use.
- Container-closure qualification.
- Clinical supply suitable for postoperative administration.
- Confirmation that legacy formulation know-how remains available.
The commercial barrier is clinical rather than manufacturing. A sponsor must show that apaziquone offers a sufficiently reliable recurrence benefit over inexpensive and familiar intravesical options.
What is the likely generic launch scenario?
No generic launch scenario exists under the current regulatory status.
If apaziquone were approved in the future, the likely sequence would be:
- Sponsor reopens development or files a new application.
- FDA accepts a redesigned clinical package.
- The sponsor obtains approval for a defined non-muscle-invasive bladder-cancer population.
- Patent and regulatory exclusivity periods begin from the new approval structure.
- ANDA or other competitive applications emerge after the applicable exclusivity and patent barriers.
- Hospital systems evaluate apaziquone against lower-cost intravesical alternatives.
The product would need a clear advantage in recurrence-free survival, safety, workflow, or patient selection to support premium pricing.
Key Takeaways
- Apaziquone, or EO9, remains an unapproved investigational intravesical bladder-cancer drug.
- Its two major Phase 3 studies failed to meet the primary efficacy objectives.
- No FDA approval, Orange Book listing, regulatory exclusivity, or commercial product exists.
- No immediate Paragraph IV or generic-launch risk is active.
- The original broad patent position is likely weakened by the age of the program and the absence of an approved reference product.
- The most credible development path would require a new sponsor, a redesigned trial, and a biomarker or high-risk population with a clearer likelihood of benefit.
- Near-term apaziquone revenue should be modeled at zero.
- A future commercial opportunity is contingent on clinical redevelopment, not merely on recovering legacy intellectual property.
FAQs About Apaziquone
Is apaziquone FDA approved for bladder cancer?
No. Apaziquone has not received FDA approval for bladder cancer or any other indication.
Can apaziquone be purchased or prescribed?
No approved commercial apaziquone product is available for routine prescription or purchase in the United States.
Did apaziquone fail because of safety?
The central development failure was inadequate efficacy in the Phase 3 program. The key issue was failure to establish the required reduction in bladder-cancer recurrence.
Is apaziquone a chemotherapy or immunotherapy?
Apaziquone is a small-molecule bioreductive cytotoxic agent. It is not a BCG-type immunotherapy and is not a biologic.
Could apaziquone return to clinical development?
Yes, but a return would require a sponsor to establish a viable regulatory and clinical strategy. The prior Phase 3 failure makes a simple relaunch unlikely.
References
-
U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Apaziquone studies in non-muscle-invasive bladder cancer. ClinicalTrials.gov.
-
Spectrum Pharmaceuticals, Inc. (2012). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
European Association of Urology. (2024). EAU guidelines on non-muscle-invasive bladder cancer. EAU Guidelines Office.
-
National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Bladder cancer. National Comprehensive Cancer Network.
-
American Urological Association. (2024). Guideline: Non-muscle-invasive bladder cancer. American Urological Association.
More… ↓
